Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.2%.
Argenx (ARGX) shares were nearly 12% higher after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.